| Schädler et al. 2013 [51] | Friesecke et al. 2017 [50] | Schädler et al. 2017 [52] | Kogelmann et al. 2017 [49] |
---|---|---|---|---|
Study design | Multicenter, open label, RCT | Prospective interventional single center | Multicenter, open label, RCT | Case series |
Study population (n) | 43 septic patients with ALI | 25 septic shock patients | 97 septic patients with ALI or ARDS | 16 septic shock patients |
IL-6 assessment (pg/ml) | – | > 1000 | Average of 565 | – |
Prescribed dose | ST vs ST + HP (6 h/day for 7 days) | One session in the pre-filter mode. Further treatments at the discretion of the study physicians | HP vs no HP (6 h/day for up to 7 days) RRT as clinically indicated in both groups | HP in the pre-filter mode (1–5 treatments) |
Timing | – | Within 24 h | – | < 24 to > 48 h (outcomes better in the early group) |
Survival | 28-day mortality 28% in the treatment group vs 24% in the controls (p = 0.84) 60-day mortality (39% in the treatment group vs 32% the controls (p = 0.75) | – | 28-day mortality 36.2% in the treatment group vs 18.0% in the controls (p = 0.073) 60-day mortality of 44.7% in the treatment group vs 26.0% in the controls (p = 0.039) | The actual 28-day, ICU, and hospital mortality was 61.54%, 73.08%, and 80.77%, respectively, compared with 89.9% as predicted by APACHE II score |
Hemodynamics | – | Significant reduction in VP requirements compared to baseline | – | Significant reduction in VP requirements compared with baseline |
Other results | Significant reduction in IL-6 | Significant reduction in IL-6 | IL-6 reduction in the HP group compared with no HP | – |
Safety | Modest reduction in platelet count (< 10%) and albumin (< 5%) | No AE | 1 drop in platelets in the treatment group | No AE |